How menstrual-cycle hormones change women's responses to cannabis
Official title: The Influence of Female Sex Hormones on the Subjective and Cognitive Response to Cannabis
Run by Maastricht University · NCT07417059 · Data updated 2026-11-12
This study will see if occasional biological female cannabis users respond differently to a measured THC dose at three phases of their menstrual cycle compared with a placebo.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 40 Years |
| Sex | Women only |
| Enrollment | 21 (estimated) |
| Sponsor | Maastricht University Academic / other |
| Locations | 1 site (Maastricht) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | February 18, 2026 |
| Trial ID | NCT07417059 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are biological females 18–40 who use cannabis occasionally (about once a month to twice a week), have regular menstrual cycles, are not on hormonal birth control or psychotropic medications, and meet health and BMI criteria.
✕Probably not a fit
People who are male, on hormonal birth control, have irregular cycles, are heavy or daily cannabis users, or have major medical or endocrine conditions are unlikely to benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a double-blind, randomized, within-subject, placebo-controlled experiment in occasional cannabis-using biological females aged 18–40. Participants will attend sessions at three defined menstrual-cycle phases and receive a single acute dose of cannabis (300 µg THC/kg bodyweight) or placebo, with order randomized. Researchers will measure subjective drug effects, multiple cognitive domains, interoception, pain responses, and THC pharmacokinetics at each session. Key eligibility requirements include regular menstrual cycles, no hormonal birth control or psychotropic medications, and a BMI between 18 and 28.
Why it matters
Potential benefit: If successful, the findings could clarify when females are most vulnerable to acute negative effects of THC and help tailor warnings, harm-reduction advice, and timing considerations for therapeutic use.
How similar studies have gone: Prior research shows sex differences in cannabis effects and faster progression to disorder in females, but controlled within-subject studies across menstrual phases are limited, so this approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Biological female * Used cannabis between 1 time a month and 2 times a week during the previous year * Age between 18 and 40 years * Free from psychotropic medication * Free from hormonal birth control * A regular menstrual cycle (last 3 cycles a duration between 21 and 35 days). * Good physical health as determined by medical examination and laboratory analysis * Absence of any major medical, endocrine and neurological condition as determined by medical examination and laboratory analysis * Normal weight, body mass index (weight/height2) between 18 and 28 kg/m2 * Written Informed Consent * Good knowledge and understanding of the English language * Participants must be willing to refrain from taking illicit psychoactive substances during the study. * Participants must be willing to drink only alcohol-free liquids and no coffee, black or green tea, or energy drinks after midnight of the evening before the study session, as well as during the study day. * Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after substance administration. Exclusion Criteria: * History of drug addiction (determined by the medical questionnaire, drug questionnaire and medical examination) * Pregnancy or lactation or pregnancy planned during study participation * Hypertension (diastolic \> 90 mmHg; systolic \> 140 mmHg) * Current or history of psychiatric disorder (determined by the medical questionnaire and medical examination) * Current presence or history of psychosis in first-degree relatives * Any chronic or acute medical condition * History of cardiac dysfunctions (arrhythmia, ischemic heart disease,…) * Tobacco smoking (\>20 per day) * Excessive drinking (\>20 alcoholic consumptions per week)
Where it's running
-
Maastricht University
Maastricht, Netherlands Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cannabis Effects on Recognition Memory and Brain Waves in Regular Users
This study tests how THC- and CBD-containing cannabis strains affect recognition memory and brain activity in regular cannabis users.
-
Hemp-based CBD topical lotion pharmacokinetics in healthy adults
This study tests how a high‑CBD, low‑THC hemp lotion behaves in the body after short‑ and longer‑term use in healthy adults.
-
Repeated CBD to change how cannabis affects mood and pain
This study will test whether taking CBD repeatedly changes the behavioral effects and pain relief experienced by adult cannabis users.
-
Effect of cannabis oil on untreatable liver cancer
This study tests whether cannabis oil can help people with untreatable liver cancer feel better by seeing if it affects their tumors.
-
Exploring how CBD affects THC's psychoactive effects
This study is testing how different amounts of CBD can change the effects of THC when people inhale them together.
-
How marijuana (THC) and tobacco interact when used together
This test tries to see if combining marijuana (THC) and tobacco changes blood drug levels and how people feel and respond physically in adults who regularly use both.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.